BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 22, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Victoza liraglutide regulatory update

The U.K.'s NICE issued a preliminary appraisal for Victoza liraglutide from Novo Nordisk to treat Type II diabetes. NICE recommended the use of the 1.2 mg dose of Victoza in triple therapy regimens (in combination with metformin and a sulfonylurea, or metformin and a thiazolidinedione). NICE also requested more information on...

Read the full 234 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >